Aprepitant attenuates NLRC4-dependent neuronal pyroptosis via NK1R/PKCδ pathway in a mouse model of intracerebral hemorrhage
Open Access
- 3 August 2022
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 19 (1) , 1-15
Abstract
Background: Pyroptosis is a programmed cell death mediated by inflammasomes. Previous studies have reported that inhibition of neurokinin receptor 1 (NK1R) exerted neuroprotection in several neurological diseases. Herein, we have investigated the role of NK1R receptor inhibition using Aprepitant to attenuate NLRC4-dependent neuronal pyroptosis after intracerebral hemorrhage (ICH), as well as the underlying mechanism. Methods: A total of 182 CD-1 mice were used. ICH was induced by injection of autologous blood into the right basal ganglia. Aprepitant, a selective antagonist of NK1R, was injected intraperitoneally at 1 h after ICH. To explore the underlying mechanism, NK1R agonist, GR73632, and protein kinase C delta (PKCδ) agonist, phorbol 12-myristate 13-acetate (PMA), were injected intracerebroventricularly at 1 h after ICH induction, and small interfering ribonucleic acid (siRNA) for NLRC4 was administered via intracerebroventricular injection at 48 h before ICH induction, respectively. Neurobehavioral tests, western blot, and immunofluorescence staining were performed. Results: The expression of endogenous NK1R and NLRC 4 were gradually increased after ICH. NK1R was expressed on neurons. Aprepitant significantly improved the short- and long-term neurobehavioral deficits after ICH, which was accompanied with decreased neuronal pyroptosis, as well as decreased expression of NLRC4, Cleaved-caspase-1, GSDMD (gasdermin D), IL-1β, and IL-18. Activation of NK1R or PKCδ abolished these neuroprotective effects of Aprepitant after ICH. Similarly, knocking down NLRC4 using siRNA produced similar neuroprotective effects. Conclusion: Aprepitant suppressed NLRC4-dependent neuronal pyroptosis and improved neurological function, possibly mediated by inhibition of NK1R/PKCδ signaling pathways after ICH. The NK1R may be a promising therapeutic target for the treatment of ICH.Keywords
Funding Information
- Shuixiang Deng (21ZR1410700)
This publication has 58 references indexed in Scilit:
- Substance P enhances microglial density in the substantia nigra through neurokinin-1 receptor/NADPH oxidase-mediated chemotaxis in miceClinical Science, 2015
- AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3Proceedings of the National Academy of Sciences, 2015
- Treatment with the NK1 Antagonist Emend Reduces Blood Brain Barrier Dysfunction and Edema Formation in an Experimental Model of Brain TumorsPLOS ONE, 2014
- Inflammasome Components Coordinate Autophagy and Pyroptosis as Macrophage Responses to InfectionmBio, 2013
- Phosphorylation of NLRC4 is critical for inflammasome activationNature, 2012
- Role of protein kinase C in caerulein induced expression of substance P and neurokinin‐1‐receptors in murine pancreatic acinar cellsJournal of Cellular and Molecular Medicine, 2011
- A mouse model of intracerebral hemorrhage using autologous blood infusionNature Protocols, 2008
- Neurokinin-1 receptor antagonism in a rat model of subarachnoid hemorrhage: prevention of upregulation of contractile ETB and 5-HT1B receptors and cerebral blood flow reductionJournal of Neurosurgery, 2007
- Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist — A putative role for substance P in CNS inflammationJournal of Neuroimmunology, 2006
- Expression of tachykinin NK1 receptor mRNA in dorsal root ganglia of the mouseMolecular Brain Research, 1996